Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.570 CHF
3.05 B CHF
8.28 B CHF
256.88 M
About Vertex Pharmaceuticals Incorporated
Sector
CEO
Reshma Kewalramani
Headquarters
Boston
Website
Founded
1989
FIGI
BBG006TLX2W2
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where VX1 is featured.
Frequently Asked Questions
The current price of VX1 is 400.979 CHF — it has decreased by −2.44% in the past 24 hours. Watch VERTEX PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange VERTEX PHARMACEUTICALS INC stocks are traded under the ticker VX1.
VX1 stock has fallen by −7.05% compared to the previous week, the month change is a −0.97% fall, over the last year VERTEX PHARMACEUTICALS INC has showed a 29.02% increase.
We've gathered analysts' opinions on VERTEX PHARMACEUTICALS INC future price: according to them, VX1 price has a max estimate of 533.96 CHF and a min estimate of 288.27 CHF. Watch VX1 chart and read a more detailed VERTEX PHARMACEUTICALS INC stock forecast: see what analysts think of VERTEX PHARMACEUTICALS INC and suggest that you do with its stocks.
VX1 stock is 2.50% volatile and has beta coefficient of 1.29. Track VERTEX PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is VERTEX PHARMACEUTICALS INC there?
Today VERTEX PHARMACEUTICALS INC has the market capitalization of 103.01 B, it has decreased by −3.45% over the last week.
Yes, you can track VERTEX PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
VERTEX PHARMACEUTICALS INC is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
VX1 earnings for the last quarter are 3.71 CHF per share, whereas the estimation was 3.46 CHF resulting in a 7.41% surprise. The estimated earnings for the next quarter are 3.61 CHF per share. See more details about VERTEX PHARMACEUTICALS INC earnings.
VERTEX PHARMACEUTICALS INC revenue for the last quarter amounts to 2.35 B CHF, despite the estimated figure of 2.28 B CHF. In the next quarter, revenue is expected to reach 2.47 B CHF.
VX1 net income for the last quarter is 885.90 M CHF, while the quarter before that showed −3.23 B CHF of net income which accounts for 127.42% change. Track more VERTEX PHARMACEUTICALS INC financial stats to get the full picture.
No, VX1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 24, 2024, the company has 5.40 K employees. See our rating of the largest employees — is VERTEX PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VERTEX PHARMACEUTICALS INC EBITDA is −74.66 M CHF, and current EBITDA margin is 45.32%. See more stats in VERTEX PHARMACEUTICALS INC financial statements.
Like other stocks, VX1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VERTEX PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VERTEX PHARMACEUTICALS INC technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VERTEX PHARMACEUTICALS INC stock shows the buy signal. See more of VERTEX PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.